Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients—a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy

PURPOSE: In the genomic era, more women with low-risk breast cancer will forego chemotherapy and rely on adjuvant endocrine therapy (AET) to prevent metastatic recurrence. However, some of these patients will unfortunately relapse. We sought to understand this outcome. Preliminary work suggested tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuhn, Elaine P., Pirruccello, Jonathan, Boothe, James T., Li, Zhongze, Tosteson, Tor D., Stahl, James E., Schwartz, Gary N., Chamberlin, Mary D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883310/
https://www.ncbi.nlm.nih.gov/pubmed/36592233
http://dx.doi.org/10.1007/s10549-022-06849-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883310/
https://www.ncbi.nlm.nih.gov/pubmed/36592233
http://dx.doi.org/10.1007/s10549-022-06849-0

Ejemplares similares